公开(公告)号：US20240043889A1

公开(公告)日：2024-02-08

申请号：US18550209

申请日：2022-03-11

Applicant: Glycom A/S

Inventor： Getachew S. MOLLA

IPC: C12P19/04 ,  C07H1/08 ,  C12N9/10

CPC classification number: C12P19/04 ,  C07H1/08 ,  C12N9/1048 ,  C12Y204/00

Abstract: The present invention relates to the isolation and purification of sialylated oligosaccharides from an aqueous medium in which they are produced.

公开(公告)号：US20230193335A1

公开(公告)日：2023-06-22

申请号：US17759270

申请日：2021-01-22

Applicant: GLYCOM A/S

Inventor： Margit PEDERSEN ,  Manos PAPADAKIS ,  Katrine Bych KAMPMANN

IPC: C12P19/04 ,  C12N9/10 ,  C12N15/70 ,  C07K14/24

CPC classification number: C12P19/04 ,  C12N9/1051 ,  C12Y204/01065 ,  C12Y204/01146 ,  C12N15/70 ,  C07K14/24

Abstract: The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic encoding a putative transporter protein of the MFS superfamily; and methods using said cell for the production of oligosaccharide(s), preferably an HMO.

公开(公告)号：US11602545B2

公开(公告)日：2023-03-14

申请号：US16770336

申请日：2018-11-30

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC: A61P25/06 ,  A61K31/702 ,  A61P1/00 ,  A61K35/20

Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing or treating migraine in a human.

公开(公告)号：US20230030220A1

公开(公告)日：2023-02-02

申请号：US17757646

申请日：2020-12-18

Applicant: Glycom A/S

Inventor： Nikolay KHANZHIN ,  Getachew S. MOLLA ,  Martin MATWIEJUK ,  Pierre CHASSAGNE

IPC: C12P19/04 ,  B01D61/14 ,  B01D61/58 ,  B01D69/02 ,  B01D71/56 ,  C12P19/26

Abstract: The present invention relates to the separation and isolation of sialylated human milk oligosaccharides (HMOs) from the reaction mixture in which they are produced.

公开(公告)号：US20230014752A1

公开(公告)日：2023-01-19

申请号：US17934123

申请日：2022-09-21

Applicant: GLYCOM A/S

Inventor： Louise Kristine VIGSNÆS ,  Bruce MCCONNELL

IPC: A61K31/702 ,  A23L33/21 ,  A23L33/00 ,  A61P1/00

Abstract: The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.

公开(公告)号：US11554131B2

公开(公告)日：2023-01-17

申请号：US17059942

申请日：2019-05-31

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Kristine Rothaus Christensen

IPC: A61K31/702 ,  A61P37/02

Abstract: The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non-intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. Said method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide (HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2′-FL, LNnT, LNT, DFL, and 6′-SL.

公开(公告)号：US11541067B2

公开(公告)日：2023-01-03

申请号：US16616338

申请日：2018-05-24

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell

IPC: A61K31/702 ,  A61K9/00 ,  A61P1/00

Abstract: A method and a composition comprising human milk oligosaccharides for decreasing the production of detrimental proteolytic metabolites such as ammonia and branched chain fatty acids in the intestinal microbiota of humans, which is useful for the treatment of brain-gut disorders like autism, stress, anxiety, and depressive disorders, are disclosed. Methods of treatment of colon cancer and liver damage are also disclosed.

公开(公告)号：US20220395520A1

公开(公告)日：2022-12-15

申请号：US17821282

申请日：2022-08-22

Applicant: GLYCOM A/S

Inventor： Nikolay KHANZHIN ,  Markus JONDELIUS HEDEROS ,  Louise Kristine VIGSNÆS ,  Bruce MCCONNELL

IPC: A61K31/702 ,  C12P19/04 ,  C12P1/04 ,  C12N9/10 ,  A61K31/716 ,  A61P31/04 ,  A61K31/7016 ,  A61K31/7032 ,  C07H1/00

Abstract: A mixture of human milk oligosaccharides that comprises or consists essentially of a) LNTri II, LNT, pLNH II and optionally lactose, or b) LNTri II, LNnT, pLNnH and optionally lactose, and is useful for preventing or treating viral or bacterial, intestinal and respiratory infections and for modulating the human gastrointestinal microbiota to increase Bifidobacterium abundance. A process for preparing the mixture and methods of crystallizing LNnT and LNT is also described.

公开(公告)号：US20220233562A1

公开(公告)日：2022-07-28

申请号：US17723135

申请日：2022-04-18

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Sami Damak ,  Norbert Sprenger ,  Francis Foata

IPC: A61K31/702 ,  A61P1/00 ,  A61K31/7016

Abstract: A method for reducing nociceptive sensitivity in non-infant humans includes in some examples selecting a non-infant human experiencing a condition and associated nociceptive sensitivity (e.g., irritable bowel syndrome or chronic neuropathic pain). In such examples, the method further includes selecting an effective amount of one or more human milk oligosaccharides (“HMOs”) chosen from the group consisting of 6′-sialyllactose (6′-SL), and a mixture of 6′-SL and lacto-N-tetraose (LNT) and reducing the nociceptive sensitivity by administering the selected effective amount of the chosen HMOs to the non-infant human during an initial phase. In some examples, the method includes activating GPR35 receptors by administering the effective amount of the chosen one or more HMOs. In some examples, the HMOs are a mixture of 6′-SL and LNT that provides a synergistic effect relative to each of the 6′-SL and LNT alone.

公开(公告)号：US20220133759A1

公开(公告)日：2022-05-05

申请号：US17577252

申请日：2022-01-17

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Elison

IPC: A61K31/702 ,  A61P25/00 ,  A61P1/00

Abstract: A method of increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal tract and regulating levels of one or both of tryptophan and serotonin in a non-infant human is disclosed. In some examples, the method is effective for treating migraines. The method includes administering for an initial treatment period an amount of one or more human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), difucosyllactose (DFL), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), where the amount is effective to increase the relative abundance of Bifidobacterium adolescentis in the gastrointestinal tract of the non-infant human.